Agrawal N, Frederick MJ, Pickering CR, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154–1157.
Alphs HH, Gambhira R, Karanam B, et al. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross‐neutralizing epitope of L2. Proceedings of the National Academy of Sciences of the United States of America 105: 5850–5855.
Ang KK, Harris J, Wheeler R, et al. (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine 363: 24–35.
Banks L, Pim D and Thomas M (2012) Human tumour viruses and the deregulation of cell polarity in cancer. Nature Reviews Cancer 12: 877–886.
Bernard HU (2013) Taxonomy and phylogeny of papillomaviruses: an overview and recent developments. Infection, Genetics and Evolution 18: 357–361.
Bernard HU, Burk RD, Chen Z, et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70–79.
Bouvard V, Baan R, Straif K, et al. (2009) A review of human carcinogens – part B: biological agents. Lancet Oncology 10: 321–322.
Buck CB, Cheng N, Thompson CD, et al. (2008) Arrangement of L2 within the papillomavirus capsid. Journal of Virology 82: 5190–5197.
Chaturvedi AK, Anderson WF, Lortet‐Tieulent J, et al. (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. Journal of Clinical Oncology 31: 4550–4559.
Chen EY, Howley PM, Levinson AD and Seeburg PH (1982) The primary structure and genetic organization of the bovine papillomavirus type 1 genome. Nature 299: 529–534.
Cheng S, Schmidt‐Grimminger DC, Murant T, Broker TR and Chow LT (1995) Differentiation‐dependent up‐regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes & Development 9: 2335–2349.
Collins SI, Constandinou‐Williams C, Wen K, et al. (2009) Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. Cancer Research 69: 3828–3832.
de Martel C, Ferlay J, Franceschi S, et al. (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncology 13: 607–615.
de Sanjose S, Quint WG, Alemany L, et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study. Lancet Oncology 11: 1048–1056.
de Villiers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17–27.
de Villiers EM, Lavergne D, McLaren K and Benton EC (1997) Prevailing papillomavirus types in non‐melanoma carcinomas of the skin in renal allograft recipients. International Journal of Cancer 73: 356–361.
de Vos van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ, et al. (2012) A placebo‐controlled randomized HPV16 synthetic long‐peptide vaccination study in women with high‐grade cervical squamous intraepithelial lesions. Cancer Immunology, Immunotherapy 61: 1485–1492.
Dochez C, Bogers JJ, Verhelst R and Rees H (2014) HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 32: 1595–1601.
Doorbar J, Quint W, Banks L, et al. (2012) The biology and life‐cycle of human papillomaviruses. Vaccine 30 (Suppl 5): F55–F70.
Durst M, Gissmann L, Ikenberg H and zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proceedings of the National Academy of Sciences of the United States of America 80: 3812–3815.
Goldstein DJ, Finbow ME, Andresson T, et al. (1991) Bovine papillomavirus E5 oncoprotein binds to the 16K component of vacuolar H(+)‐ATPases. Nature 352: 347–349.
Goodwin EC and DiMaio D (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proceedings of the National Academy of Sciences of the United States of America 97: 12513–12518.
zur Hausen H (1977) Human papillomaviruses and their possible role in squamous cell carcinomas. Current Topics in Microbiology and Immunology 78: 1–30.
Herfs M, Yamamoto Y, Laury A, et al. (2012) A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proceedings of the National Academy of Sciences of the United States of America 109: 10516–10521.
Ingle A, Ghim S, Joh J, et al. (2011) Novel laboratory mouse papillomavirus (MusPV) infection. Veterinary Pathology 48: 500–505.
Jablonska S, Dabrowski J and Jakubowicz K (1972) Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Research 32: 583–589.
Jackson S, Harwood C, Thomas M, Banks L and Storey A (2000) Role of Bak in UV‐induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes & Development 14: 3065–3073.
Joura EA, Ault KA, Bosch FX, et al. (2014) Attribution of 12 high‐risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiology, Biomarkers & Prevention 23: 1997–2008.
Kines RC, Thompson CD, Lowy DR, Schiller JT and Day PM (2009) The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proceedings of the National Academy of Sciences of the United States of America 106: 20458–20463.
Kiyono T, Hiraiwa A, Fujita M, et al. (1997) Binding of high‐risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proceedings of the National Academy of Sciences of the United States of America 94: 11612–11616.
Korzeniewski N, Spardy N, Duensing A and Duensing S (2011) Genomic instability and cancer: Lessons learned from human papillomaviruses. Cancer Letters 305: 113–122.
Maglennon GA, McIntosh P and Doorbar J (2011) Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414: 153–163.
Moody CA and Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer 10: 550–560.
Papanicolaou GN (1948) The cell smear method of diagnosing cancer. American Journal of Public Health and the Nation's Health 38: 202–205.
Ramoz N, Rueda LA, Bouadjar B, et al. (2002) Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nature Genetics 32: 579–581.
Roberts JN, Buck CB, Thompson CD, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol‐9 and inhibited by carrageenan. Nature Medicine 13: 857–861.
Rous P and Beard JW (1935) The progression to carcinoma of virus‐induced rabbit papillomas (shope). Journal of Experimental Medicine 62: 523–548.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136.
Stanley MA, Moore RA, Nicholls PK, et al. (2001) Intra‐epithelial vaccination with COPV L1 DNA by particle‐mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19: 2783–2792.
Stransky N, Egloff AM, Tward AD, et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157–1160.
Tenge VR, Gounder AP, Wiens ME, Lu W and Smith JG (2014) Delineation of interfaces on human alpha‐defensins critical for human adenovirus and human papillomavirus inhibition. PLoS Pathogens 10: e1004360.
Walboomers JM, Jacobs MV, Manos MM, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 189: 12–19.
Werness BA, Levine AJ and Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76–79.
Wetherill LF, Holmes KK, Verow M, et al. (2012) High‐risk human papillomavirus E5 oncoprotein displays channel‐forming activity sensitive to small‐molecule inhibitors. Journal of Virology 86: 5341–5351.
Woodman CB, Collins SI and Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 7: 11–22.
Bravo IG, de Sanjose S and Gottschling M (2010) The clinical importance of understanding the evolution of papillomaviruses. Trends in Microbiology 18: 432–438.
Cardone G, Moyer AL, Cheng N, et al. (2014) Maturation of the human papillomavirus 16 capsid. MBio 5: e01104–e01114.
D'Souza G, Kreimer AR, Viscidi R, et al. (2007) Case‐control study of human papillomavirus and oropharyngeal cancer. New England Journal of Medicine 356: 1944–1956.
Gravitt PE (2012) Evidence and impact of human papillomavirus latency. Open Virology Journal 6: 198–203.
Latini A, Dona MG, Ronchetti L, et al. (2014) Prevalence of anal human papillomavirus infection and cytologic abnormalities among HIV‐infected and HIV‐uninfected men who have sex with men. Journal of the International AIDS Society 17: 19662.
Marur S, D'Souza G, Westra WH and Forastiere AA (2010) HPV‐associated head and neck cancer: a virus‐related cancer epidemic. The Lancet Oncology 11: 781–789.
Mehanna H, Beech T, Nicholson T, et al. (2013) Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer – systematic review and meta‐analysis of trends by time and region. Head & Neck 35: 747–755.
Rector A and Van Ranst M (2013) Animal papillomaviruses. Virology 445: 213–223.
Schiller JT and Lowy DR (2012) Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Reviews Microbiology 10: 681–692.
Stanley MA (2012) Epithelial cell responses to infection with human papillomavirus. Clinical Microbiology Reviews 25: 215–222.